company background image
VAIS

Vaishali Pharma NSEI:VAISHALI Stock Report

Last Price

₹86.35

Market Cap

₹910.7m

7D

-2.7%

1Y

95.6%

Updated

16 Aug, 2022

Data

Company Financials
VAISHALI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health4/6
Dividends0/6

VAISHALI Stock Overview

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally.

Vaishali Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaishali Pharma
Historical stock prices
Current Share Price₹86.35
52 Week High₹119.30
52 Week Low₹28.95
Beta0.58
1 Month Change4.86%
3 Month Change2.74%
1 Year Change95.58%
3 Year Change213.29%
5 Year Changen/a
Change since IPO122.48%

Recent News & Updates

May 19
Should You Be Adding Vaishali Pharma (NSE:VAISHALI) To Your Watchlist Today?

Should You Be Adding Vaishali Pharma (NSE:VAISHALI) To Your Watchlist Today?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

VAISHALIIN PharmaceuticalsIN Market
7D-2.7%0.2%1.9%
1Y95.6%-11.7%9.1%

Return vs Industry: VAISHALI exceeded the Indian Pharmaceuticals industry which returned -12% over the past year.

Return vs Market: VAISHALI exceeded the Indian Market which returned 8.3% over the past year.

Price Volatility

Is VAISHALI's price volatile compared to industry and market?
VAISHALI volatility
VAISHALI Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.1%

Stable Share Price: VAISHALI is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: VAISHALI's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198932Hemant Pathakhttps://www.vaishalipharma.com

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations.

Vaishali Pharma Fundamentals Summary

How do Vaishali Pharma's earnings and revenue compare to its market cap?
VAISHALI fundamental statistics
Market Cap₹910.67m
Earnings (TTM)₹47.23m
Revenue (TTM)₹777.31m

19.3x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VAISHALI income statement (TTM)
Revenue₹777.31m
Cost of Revenue₹637.61m
Gross Profit₹139.70m
Other Expenses₹92.47m
Earnings₹47.23m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.48
Gross Margin17.97%
Net Profit Margin6.08%
Debt/Equity Ratio79.0%

How did VAISHALI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VAISHALI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VAISHALI?

Other financial metrics that can be useful for relative valuation.

VAISHALI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.4x
Enterprise Value/EBITDA14.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does VAISHALI's PE Ratio compare to its peers?

VAISHALI PE Ratio vs Peers
The above table shows the PE ratio for VAISHALI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average46.2x
531739 Gennex Laboratories
21.2xn/a₹832.4m
524506 Coral Laboratories
18.1xn/a₹873.7m
524202 Lactose (India)
29.6xn/a₹945.4m
524396 Biofil Chemicals and Pharmaceuticals
116xn/a₹847.9m
VAISHALI Vaishali Pharma
19.3xn/a₹910.7m

Price-To-Earnings vs Peers: VAISHALI is good value based on its Price-To-Earnings Ratio (19.3x) compared to the peer average (46.2x).


Price to Earnings Ratio vs Industry

How does VAISHALI's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: VAISHALI is good value based on its Price-To-Earnings Ratio (19.3x) compared to the Indian Pharmaceuticals industry average (22.6x)


Price to Earnings Ratio vs Fair Ratio

What is VAISHALI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VAISHALI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VAISHALI's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of VAISHALI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VAISHALI (₹86.35) is trading above our estimate of fair value (₹18.78)

Significantly Below Fair Value: VAISHALI is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Vaishali Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


19.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaishali Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Vaishali Pharma performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


49.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VAISHALI has high quality earnings.

Growing Profit Margin: VAISHALI's current net profit margins (6.1%) are higher than last year (3.2%).


Past Earnings Growth Analysis

Earnings Trend: VAISHALI's earnings have grown significantly by 49.3% per year over the past 5 years.

Accelerating Growth: VAISHALI's earnings growth over the past year (154.5%) exceeds its 5-year average (49.3% per year).

Earnings vs Industry: VAISHALI earnings growth over the past year (154.5%) exceeded the Pharmaceuticals industry -0.3%.


Return on Equity

High ROE: VAISHALI's Return on Equity (17.9%) is considered low.


Discover strong past performing companies

Financial Health

How is Vaishali Pharma's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: VAISHALI's short term assets (₹764.3M) exceed its short term liabilities (₹519.4M).

Long Term Liabilities: VAISHALI's short term assets (₹764.3M) exceed its long term liabilities (₹33.3M).


Debt to Equity History and Analysis

Debt Level: VAISHALI's net debt to equity ratio (73.8%) is considered high.

Reducing Debt: VAISHALI's debt to equity ratio has reduced from 266.2% to 79% over the past 5 years.

Debt Coverage: VAISHALI's debt is not well covered by operating cash flow (6.3%).

Interest Coverage: VAISHALI's interest payments on its debt are well covered by EBIT (3.1x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Vaishali Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VAISHALI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VAISHALI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VAISHALI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VAISHALI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VAISHALI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Hemant Pathak (61 yo)

2.25yrs

Tenure

Mr. Hemant Damodar Pathak serves as Chief Executive Officer of Vaishali Pharma Limited May 26, 2020. He has good experience in the field International Business Development as exposure to more than 90 count...


Leadership Team

Experienced Management: VAISHALI's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: VAISHALI's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vaishali Pharma Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Vaishali Pharma Limited
  • Ticker: VAISHALI
  • Exchange: NSEI
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹910.665m
  • Shares outstanding: 10.55m
  • Website: https://www.vaishalipharma.com

Number of Employees


Location

  • Vaishali Pharma Limited
  • 706 to 709, Aravalli Business Center
  • 7th Floor
  • Mumbai
  • Maharashtra
  • 400092
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.